D3
An anti-SARS-CoV-2 monoclonal antibody.
General information
D3 is a monoclonal antibody that neutralizes the SARS-CoV-2 virus in vitro. It is a human IgG4 antibody targeting the RBD spike protein on the surface of the virus. This may prevent the spike protein from interacting with the ACE2 receptor on human cells, thereby blocking the virus from infecting the cells. In addition, D3 was found to be effective in neutralizing the B.1.1.7 variant of the virus in human cell cultures (Passariello et al., 2021). When D3 is combined with Sotrovimab, they recognize distinct epitopes and have an additional inhibitory effect on the interaction between the Omicron-RBD and the ACE2 receptor (Passariello et al., 2022).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab
Spike protein Spike variant Protein factor In vitro Antibody |
Human nasal epithelial cells from healthy donors | D3 can be combined with sotrovimab as a treatment option for SARS-CoV-2 infection, especially the Omicron variant. |
May/16/2022 | |
|
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
Spike protein Novel compound Protein factor In vitro Mechanism Antibody |
Human primary nasal epithelial cells | The substance D3 is effective in neutralizing the B.1.1.7 variant of SARS-CoV-2 without any harmful toxic or pro-inflammatory side effects. |
May/26/2021 |
